Clinical Trials

A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma

Study ID
Bristol-Myers Squibb CA224-060

NCT Number
NCT03662659 (Click on the NCT number for more information about the trial)

Research Study Number

Principle Investigator
Dr. Martin Gutierrez


Bristol-Myers Squibb

Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at

Apply Now